Mineralys Therapeutics, a biopharmaceutical company developing treatments for hypertension and related conditions, will announce its financial results for Q3 2026 on November 4 after market close. The company will host a conference call and webcast for investors to discuss the results. This update follows recent positive clinical trial data for its lead drug candidate, lorundrostat, which targets aldosterone-related diseases. Investors will be watching for financial performance alongside ongoing drug development progress.
Mineralys Therapeutics is set to announce its Q3 2026 financial results on November 4. For readers following Health-sector stocks, here is Pluang's market snapshot as of Oct 29, 2026 03:21 WIB: Out of 150 priced Health-sector US stocks tradable on Pluang, 103 rose and 46 fell today. Notable movers include TDOC (Teladoc Health Inc) at USD 7.55 with a 1-day change of +17.05% and a typical hold time on Pluang of 39 days, SLS (SELLAS Life Sciences Group Inc.) at USD 10.38 down -14.71% with a typical hold time of 7 days, and CLPT (ClearPoint Neuro Inc) at USD 10.57 up +9.08% with balanced Pluang order activity and a typical hold time of 11 days.
SpaceX reported a strong Q3 with revenue up 161% year-over-year to $14.6 billion and a net profit of $4.4 billion, reversing last year's loss. Starlink, its satellite internet service, grew revenue by nearly 70% to $5.2 billion and added 1.6 million ...
SPIE, a leading European multi-technical services provider, has signed an agreement to acquire a 76% stake in SAR ANLAGENBAU GmbH, a major electrical engineering and automation firm based in Austria and Germany. This acquisition will enhance SPIE's p...
SPIE, a European leader in energy and communication services, has agreed to acquire a 76% stake in SAR ANLAGENBAU GmbH, a key electrical engineering and automation firm in Austria and Germany. This acquisition will broaden SPIE's service portfolio in...
The global dermatological therapeutics market is projected to grow from about $43 billion in 2025 to $97 billion by 2034, with a compound annual growth rate of around 10%. This growth is fueled by increasing cases of acne, psoriasis, and other chroni...
Blockchain.com has launched TRX options trading, providing easier access to TRON's native token through its platform. This move expands the TRON ecosystem's reach by simplifying options trading for retail and institutional users worldwide. TRON, know...
